
Release date: 2026-05-08 13:54:18 Article From: Lucius Laos Recommended: 29
Patients who are allergic to baloxavir marboxil or any other ingredients in Xofluza should not use this product. Allergic reactions may manifest as facial or skin swelling, itchy rash, difficulty breathing, decreased blood pressure, etc. If these occur, seek immediate medical attention. Additionally, infants younger than 3 weeks of age should not use Xofluza because the safety and efficacy in this age group have not been established. If you are pregnant, breastfeeding, or planning to become pregnant, avoid using Xofluza as a precaution; if necessary, consult your doctor to weigh the benefits and risks. Furthermore, individuals with known intolerance to certain sugars (e.g., fructose, lactose) should use caution, as this product contains lactose.
Before taking Xofluza, be sure to inform your doctor of your complete health status, including whether you have underlying liver disease, kidney disease, are pregnant or breastfeeding, and whether you have any allergies. For infants and children, use is only approved for those aged 3 weeks and older, and the dose must be accurately calculated based on body weight. Xofluza is unlikely to affect your ability to drive or operate machinery, as no significant central nervous system side effects were observed in clinical trials. Additionally, each tablet of Xofluza contains less than 1 mmol (23 mg) of sodium, essentially making it a "sodium-free" drug, so it is generally safe for patients who need to limit sodium intake. However, the lactose component may cause gastrointestinal discomfort in those with lactose intolerance.
While taking Xofluza, avoid concomitant use of the following drugs or supplements: laxatives, antacids (acid neutralizers), and any oral dietary supplements containing iron, zinc, selenium, calcium, or magnesium. These products, due to their metal ions or alkaline components, can bind to baloxavir marboxil and significantly reduce its absorption in the gastrointestinal tract, thereby diminishing its antiviral effect. If you are taking other prescription or over-the-counter medications, especially those containing polyvalent cations, be sure to inform your doctor or pharmacist in advance. It is recommended to separate the administration of Xofluza and these products by at least several hours, but given the single-dose nature of Xofluza, the safest approach is to simply avoid using them during the treatment period.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3112025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5282024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3122025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3262025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3022025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3562025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2792025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: